Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950591 | 0.89 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1ERN1MEN1KMT2A | |
| SCHEMBL3292146 | 0.85 | HPGD (0.46) | MEN1KMT2AGAATDP1CYP17A1 | |
| SCHEMBL29956441 | 0.85 | HPGD (0.46) | MEN1KMT2AGAATDP1CYP17A1 | |
| SCHEMBL13694734 | 0.85 | HPGD (0.49) | ERN1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL31718057 | 0.85 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1MEN1KMT2AATR | |
| SCHEMBL16800072 | 0.85 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1MEN1KMT2AATR | |
| SCHEMBL16800071 | 0.85 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1MEN1KMT2AATR | |
| SCHEMBL29956545 | 0.84 | MIF (0.43) | MEN1KMT2AATRPDK1PDK2 | |
| SCHEMBL29954656 | 0.84 | KCNQ4 (0.46) | ATRGAACYP17A1CA12CA1 | |
| SCHEMBL5425869 | 0.84 | CA12 (0.49) | GAACYP17A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132137-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYSTALLINE FORMS THEREOF | HOFFMANN LA ROCHE INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459947-B2 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof | HOFFMANN-LA ROCHE INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | Neumora Therapeutics, Inc. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3894414-B1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2023-03-23 | — | — | US | disclosed |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3894414-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | Blackthorn Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210284648-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-11040977-B2 | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof | HOFFMANN-LA ROCHE INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3077396-B1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020123872-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20190194210-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10246460-B2 | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof | HOFFMANN-LA ROCHE INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20160280712-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280712-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015082370-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284648-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | CPNE4, CRYZ, CYP2A7 | HSP90AA1 4025/4885HSP90AB1 3973/4885ERN1 3962/4885 |
| US-20160280712-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | CRYZ, CPNE4, CYP2A7 | HSP90AA1 3667/4885HSP90AB1 3613/4885ERN1 3854/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | HSP90AA1 2133/4885HSP90AB1 1946/4885ERN1 2960/4885 |
| US-20260132137-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYSTALLINE FORMS THEREOF | YWHAQ, CCT8, CYP2C18 | HSP90AA1 4479/4885HSP90AB1 4426/4885ERN1 2515/4885 |
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | AVPR1B, AVPR1A, AVPR2 | HSP90AA1 1302/4885HSP90AB1 928/4885ERN1 4487/4885 |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | HSP90AA1 2133/4885HSP90AB1 1946/4885ERN1 2960/4885 |
| US-11040977-B2 | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof | CPNE4, CRYZ, CYP2A7 | HSP90AA1 4025/4885HSP90AB1 3973/4885ERN1 3962/4885 |
| US-10246460-B2 | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof | CRYZ, CPNE4, CYP2A7 | HSP90AA1 3667/4885HSP90AB1 3613/4885ERN1 3854/4885 |
| US-20190194210-A1 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF | CPNE4, CRYZ, CYP2A7 | HSP90AA1 4025/4885HSP90AB1 3973/4885ERN1 3962/4885 |
| US-12459947-B2 | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof | NT5C, CYP8B1, AZI2 | HSP90AA1 3459/4885HSP90AB1 3532/4885ERN1 3274/4885 |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | AVPR1B, AVPR1A, AVPR2 | HSP90AA1 1754/4885HSP90AB1 1548/4885ERN1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.